MSU
TVRD

Mizuho Securities USA’s Tvardi Therapeutics TVRD Stock Holding History

Mizuho Securities USA’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,153
Closed -$1.35M – 210
2017
Q1 		$1.35M Buy
+2,153
New +$1.15M 0.07% 59

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mizuho Securities USA's TVRD Position: Q2 2017 in Review

Mizuho Securities USA sold out of Tvardi Therapeutics (TVRD) in Q2 2017, closing a stake of 2,153 shares — an estimated $1.35M sold.

Mizuho Securities USA first reported a position in TVRD in Q1 2017 and held it in 1 quarter. The position peaked at $1.35M in Q1 2017. 127 funds tracked by Wall St. Rank hold TVRD as of Q2 2017.

  • Mizuho Securities USA reported no remaining Tvardi Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Mizuho Securities USA sold 2,153 Tvardi Therapeutics shares in Q2 2017, an estimated $1.35M.
  • Mizuho Securities USA first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 1 quarter.
  • Mizuho Securities USA's Tvardi Therapeutics position peaked at $1.35M in Q1 2017.
  • 127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2017.

Based on Mizuho Securities USA's 13F filing for Q2 2017, filed 21 Jul 2017.